Intermittent claudication: An overview

  • Ashwinkumar V. Meru
    Corresponding author. Tel.: +91 124 5195277; fax: +91 124 2343545.
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Limited, R&D, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122001, Haryana, India
    Search for articles by this author
  • Shivani Mittra
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Limited, R&D, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122001, Haryana, India
    Search for articles by this author
  • Baskaran Thyagarajan
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Limited, R&D, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122001, Haryana, India
    Search for articles by this author
  • Anita Chugh
    New Drug Discovery Research, Department of Pharmacology, Ranbaxy Laboratories Limited, R&D, Plot 20, Sector 18, Udyog Vihar Industrial Area, Gurgaon 122001, Haryana, India
    Search for articles by this author


      Intermittent claudication (IC) is defined by leg muscle pain, cramping and fatigue brought on by ambulation/exercise; relieved on rest; and caused by inadequate blood supply and is the primary symptom of peripheral arterial disease (PAD). PAD has a detrimental effect on the quality of life. PAD is a debilitating atherosclerotic disease of the lower limbs and is associated with an increased risk of cardiovascular morbidity and mortality. IC is an extremely important marker of atheroma. Up to 60% patients with IC have significant underlying coronary and/or carotid disease and 40% of all patients suffering from IC die or suffer a stroke within 5 years of presentation. The therapeutic intervention of IC essentially aims at providing symptomatic relief and reducing the systemic cardiovascular complications. Although exercise therapy is one of the most efficacious conservative treatments for claudication, the pharmacotherapeutic goals can be best achieved through an increase in the walking capacity to improve quality of life and a decrease in rates of amputation. In the development of treatment for IC, an aggressive non-pharmacological intervention and pharmacological treatment of the risk factors associated with IC are considered. In the next 2 years, the results of major trials of drugs that stabilize and regress atherosclerosis such as statins and angiotensin converting enzyme inhibitors, and anti-platelet agents, recombinant growth factors and immune modulators will be available for IC. Levocarnitine (l-carnitine) and a derivative, propionyl levocarnitine, are emerging agents that increase the pain-free walking and improve the quality of life in IC patients by working at the metabolism and exercise performance of ischemic muscles. This article provides a comprehensive review of the pathophysiology involved, diagnosis of IC and existing and emerging pharmacotherapies with rationale for their use in its treatment.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bick C.
        Intermittent claudication.
        Nurs Stand. 2003; 17: 45-52
        • Duprez D.A.
        • De Buyzere M.L.
        • Hirsch A.T.
        Developing pharmaceutical treatments for peripheral artery disease.
        Expert Opin Investig Drugs. 2003; 12: 101-108
        • Hiatt W.R.
        Pharmacologic therapy for peripheral arterial disease and claudication.
        J Vasc Surg. 2002; 36: 1283-1291
        • Lanzer P.
        Vascular multimorbidity in patients with a documented coronary artery disease.
        Z Kardiol. 2003; 8: 650-659
        • Schmieder F.A.
        Intermittent claudication: magnitude of the problem, patient evaluation, and therapeutic strategies.
        Am J Cardiol. 2001; 87: 3D-13D
      1. Murray S. Vascular disease: nursing and management. Whurr Publishers, London2001
        • Leng G.C.
        • Lee A.J.
        • Fowkes F.G.
        • et al.
        Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population.
        Int J Epidemiol. 1996; 25: 1172-1181
        • Muluk S.C.
        • Muluk V.S.
        • Kelley M.E.
        • et al.
        Outcome events in patients with claudication: a 15-year study in 2777 patients.
        J Vasc Surg. 2001; 33 ([discussion 57–8]): 251-257
        • Jelnes R.
        • Gaardsting O.
        • Hougaard Jensen K.
        • et al.
        Fate in intermittent claudication: outcome and risk factors.
        Br Med J (Clin Res Ed). 1986; 293: 1137-1140
        • Criqui M.H.
        • Langer R.D.
        • Fronek A.
        • et al.
        Mortality over a period of 10 years in patients with peripheral arterial disease.
        N Engl J Med. 1992; 326: 381-386
        • Howell M.A.
        • Colgan M.P.
        • Seeger R.W.
        • Ramsey D.E.
        • Sumner D.S.
        Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study.
        J Vasc Surg. 1989; 9 ([discussion 96–7]): 691-696
        • McKenna M.
        • Wolfson S.
        • Kuller L.
        The ratio of ankle and arm arterial pressure as an independent predictor of mortality.
        Atherosclerosis. 1991; 87: 119-128
        • Rehring T.F.
        • Sandhoff B.G.
        • Stolcpart R.S.
        • Merenich J.A.
        • Hollis Jr., H.W.
        Atherosclerotic risk factor control in patients with peripheral arterial disease.
        J Vasc Surg. 2005; 41: 816-822
        • Hiatt W.R.
        Carnitine and peripheral arterial disease.
        Ann N Y Acad Sci. 2004; 1033: 92-98
        • Jacoby D.
        • Mohler 3rd, E.R.
        Drug treatment of intermittent claudication.
        Drugs. 2004; 64: 1657-1670
        • Castano G.
        • Mas R.
        • Roca J.
        • et al.
        A double blind, placebo-controlled study of the effects of policosanol in patients with intermittent claudication.
        Angiology. 1999; 50: 123-130
        • Lederman R.J.
        • Mendelsohn F.O.
        • Anderson R.D.
        • et al.
        Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomized trial.
        Lancet. 2002; 359: 2053-2058
        • de Vries M.
        • Ouwendijk R.
        • Kessels A.G.
        • et al.
        Comparison of generic and disease-specific questionnaires for the assessment of quality of life in patients with peripheral arterial disease.
        J Vasc Surg. 2005; 41: 261-268
        • Trans-Atlantic Inter-Society Consensus (TASC)
        Management of peripheral arterial disease (PAD).
        Eur J Vasc Endovasc Surg. 2000; 19: S1-S250
        • Labs K.H.
        • Dormandy J.A.
        • Jaeger K.A.
        • Stuerzebecher C.S.
        • Hiatt W.R.
        Transatlantic conference on clinical trial guidelines in peripheral arterial disease: clinical trial methodology. Basel PAD Clinical Trial Methodology Group.
        Circulation. 1999; 100: e75-e81
        • Dormandy J.A.
        • Rutherford R.B.
        Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).
        J Vasc Surg. 2003; 31: S1-S296
        • Weitz J.I.
        • Byrne J.
        • Clagett G.P.
        • et al.
        Diagnosis and treatment of chronic arterial insufficiency of the lower extremities: a critical review.
        Circulation. 1996; 94: 3026-3049
        • Diehm C.
        Epidemiology of peripheral arterial disease.
        Vasa. 2004; 33: 183-189
        • Ouriel K.
        Comparison of surgical and thrombolytic treatment of peripheral arterial disease.
        Rev Cardiovasc Med. 2002; 3: S7-S16
        • Ouriel K.
        • Zarins C.K.
        Doppler ankle pressure: an evaluation of three methods of expression.
        Arch Surg. 1982; 117: 1297-1300
        • Rose S.C.
        Noninvasive vascular laboratory for evaluation of peripheral arterial occlusive disease: Part II—clinical applications: chronic, usually atherosclerotic, lower extremity ischemia.
        J Vasc Interv Radiol. 2000; 11: 1257-1275
        • Hayoz D.
        • Bounameaux H.
        • Canova C.R.
        Swiss Atherothrombosis Survey: a field report on the occurrence of symptomatic and asymptomatic peripheral arterial disease.
        J Intern Med. 2005; 258: 238-243
        • Kannel W.B.
        • McGee D.L.
        Update on some epidemiologic features of intermittent claudication: the Framingham Study.
        J Am Geriatr Soc. 1985; 33: 8-13
        • Ingolfsson I.Ö.
        • Sigurdsson G.
        • Sigvaldson H.
        • Thorgeirsson G.
        • Sigfusson N.
        A marked decline in the prevalence and incidence of intermittent claudication in Icelandic men 1968–1986: a strong relationship to smoking and serum cholesterol—the Reykjavik Study.
        J Clin Epidemiol. 1994; 47: 1237-1243
        • Bowlin S.J.
        • Medalie J.H.
        • Flocke S.A.
        • Zyzanski S.J.
        • Goldbourt U.
        Epidemiology of intermittent claudication in middle-aged men.
        Am J Epidemiol. 1994; 140: 418-430
        • Criqui M.H.
        • Fronek A.
        • Barrett-Connor E.
        • et al.
        The prevalence of peripheral arterial occlusive disease in a defined population.
        Circulation. 1985; 71: 510-515
        • Kannel W.B.
        • McGee D.L.
        Update on some epidemiologic features of intermittent claudication: the Framingham Study.
        J Am Geriatr Soc. 1985; 33: 13-18
        • Bainton D.
        • Sweetnam P.
        • Baker I.
        • Elwood P.
        Peripheral vascular disease: consequence for survival and association with risk factors in the Speedwell Prospective Heart Disease Study.
        Br Heart J. 1994; 72: 128-132
        • Dagenais G.R.
        • Maurice S.
        • Robitaille N.-M.
        • Gingras S.
        • Lupien P.J.
        Intermittent claudication in Quebec men from 1974–1986: the Quebec Cardiovascular Study.
        Clin Invest Med. 1991; 14: 93-100
        • Baron A.D.
        Vascular reactivity.
        Am J Cardiol. 1999; 84: 25J-27J
        • Blake G.J.
        • Ridker P.M.
        Inflammatory biomarkers and cardiovascular risk prediction.
        J Intern Med. 2002; 252: 283-294
        • Ursella S.
        • Mazzone M.
        • Portale G.
        • et al.
        How to use the C-reactive protein in cardiac diseases.
        Minerva Cardioangiol. 2005; 53: 59-68
        • Riba R.
        • Nicolaou A.
        • Troxler M.
        • et al.
        Altered platelet reactivity in peripheral vascular disease complicated with elevated plasma homocysteine levels.
        Atherosclerosis. 2004; 175: 69-75
        • Mueller T.
        • Dieplinger B.
        • Gegenhuber A.
        • et al.
        Serum total 8-iso-prostaglandin F: a new and independent predictor of peripheral arterial disease.
        J Vasc Surg. 2004; 40: 768-773
        • Morrow J.D.
        The isoprostanes: their quantification as an index of oxidant stress status in vivo.
        Drug Metab Rev. 2000; 32: 377-385
        • Robert L.J.
        • Morrow J.D.
        Measurement of F(2)-isoprotanes as an index of oxidative stress in vivo.
        Free Radic Biol Med. 2000; 28: 505-513
        • Blann A.D.
        • Lip G.Y.
        Virchow's triad revisited: the importance of soluble coagulation factors, the endothelium, and platelets.
        Thromb Res. 2001; 101: 321-327
        • Behrendt D.
        • Ganz P.
        Endothelial function from vascular biology to clinical applications.
        Am J Cardiol. 2002; 90: 40L-48L
        • Ross R.
        Atherosclerosis—an inflammatory disease.
        N Engl J Med. 1999; 340: 115-126
        • Makin A.
        • Silverman S.H.
        • Lip G.Y.H.
        Peripheral vascular disease and virchow's triad for thrombogenesis.
        QJM. 2002; 95: 199-210
        • Boneu B.
        • Abbal M.
        • Plante J.
        • Bierme R.
        Factor-VIII complex and endothelial damage.
        Lancet. 1975; i: 1430
        • Mutin M.
        • Canavy I.
        • Blann A.
        • et al.
        Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells.
        Blood. 1999; 93: 2951-2958
        • Blann A.D.
        • Seigneur M.
        • Steiner M.
        • Boisseau M.R.
        • McCollum C.N.
        Circulating endothelial cell markers in peripheral vascular disease: relationship to the location and extent of atherosclerotic disease.
        Eur J Clin Invest. 1997; 27: 916-921
        • Tisi P.
        • Shearman C.
        The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking?.
        Eur J Vasc Endovasc Surg. 1998; 15: 7-17
        • Edwards A.T.
        • Blann A.D.
        • Suarez-Mendez V.J.
        • Lardi A.M.
        • McCollum C.N.
        Systemic response in patients with intermittent claudication after treadmill exercise.
        Br J Surg. 1994; 81: 1738-1741
        • Viles-Gonzalez J.F.
        • Fuster V.
        • Badimon J.J.
        Atherosclerosis: a widespread disease with unpredictable and life threatening consequences.
        Eur Heart J. 2004; 25: 1197-1207
        • Blann A.D.
        • McCollum C.N.
        Circulating endothelial cell/leukocyte adhesion molecules in atherosclerosis.
        Thromb Haemost. 1994; 72: 151-154
        • Cassar K.
        • Bachoo P.
        • Brittenden J.
        The role of platelets in peripheral vascular disease.
        Eur J Vasc Endovasc Surg. 2003; 25: 6-15
        • Ouriel K.
        Peripheral arterial disease.
        Lancet. 2001; 358: 1257-1264
        • Schoop W.
        • Leny H.
        Prevention of peripheral arteroal occlusive disease with antiaggregants.
        Thromb Haemost. 1983; : 50-137
        • Harker L.A.
        Role of platelets and thrombosis in mechanisms of acute occlusion and restenosis after angioplasty.
        Am J Cardiol. 1987; 60: 20-28
        • Bradbury A.W.
        The role of cilostazol (pletal) in the management of intermittent claudication.
        Int J Clin Pract. 2003; 57: 405-409
        • Hiatt W.R.
        • Hoag S.
        • Hammen R.F.
        Effect of diagnostic criteria on the prevalence of peripheral arterial disease.
        Circulation. 1995; 92: 1472-1479
        • Reunanen A.
        • Takkunen H.
        • Aromaa A.
        Prevalence of intermittent claudication and its effect on mortality.
        Acta Med Scan. 1982; 211: 249-256
        • Murabito J.M.
        Temporal trends in the incidence of intermittent claudication from 1950 to 1999.
        Am J Epidemiol. 2005; 162 ([Epub 2005]): 430-437
        • Hobbs J.
        Varicose veins.
        in: Wolfe J. ABC of vascular diseases. British Medical Journal, London1995: 51-54
        • Criqui M.H.
        Systemic atherosclerosis risk and the mandate for intervention in atherosclerotic peripheral arterial disease.
        Am J Cardiol. 2001; 88: 43J-47J
        • Smith Jr., S.C.
        • Blair S.N.
        • Bonow R.O.
        • et al.
        AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology.
        Circulation. 2001; 104: 1577-1579
      2. Third report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143–421.

        • Dormandy J.A.
        • Rutherford R.B.
        Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC).
        J Vasc Surg. 2003; 31: S1-S296
        • Chaudhary H.
        • Holland A.
        • Dormandy J.
        Comparison of graded versus constant treadmill test protocols for quantifying intermittent claudication.
        Vasc Med. 1997; 2: 93-97
        • Schainfeld R.M.
        Management of peripheral arterial disease and intermittent claudication.
        J Am Board Fam Pract. 2001; 14: 443-450
        • Hashiguchi M.
        • Ohno K.
        • Saito R.
        Studies on the effectiveness and safety of cilostazol, beraprost sodium, prostaglandin E1 for the treatment of intermittent claudication.
        Yakugaku Zasshi. 2004; 124: 321-332
        • Antiplatelet Trialists’ Collaboration
        Collaborative overview of randomised trials of antiplatelet therapy—I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.
        BMJ. 1994; 308: 81-106
      3. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988;2:349–60.

        • Antithrombotic Trialists’ Collaboration
        Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
        BMJ. 2002; 324: 71-86
        • Krupski W.C.
        • Weiss D.G.
        • Rapp J.H.
        • Corson J.D.
        • Hobson 2nd, R.W.
        Adverse effects of aspirin in the treatment of asymptomatic carotid artery stenosis. The VA Cooperative Asymptomatic Carotid Artery Stenosis Study Group.
        J Vasc Surg. 1992; 16: 588-597
        • Hess H.
        • Mietaschk A.
        • Deichsel G.
        Drug induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double blind arteriographically controlled trial.
        Lancet. 1985; 1: 415-419
        • Dorffler-Melly J.
        • Koopman M.M.
        • Prins M.H.
        • Buller H.R.
        Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment.
        Cochrane Database Syst Rev. 2005; : CD002071
        • Girolami B.
        • Bernardi E.
        • Prins M.H.
        • et al.
        Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis.
        Eur J Vasc Endovasc Surg. 2000; 19: 370-380
        • CAPRIE Steering Committee
        A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Schleinitz M.D.
        • Weiss J.P.
        • Owens D.K.
        Clopidogrel versus aspirin for secondary prophylaxis of vascular events: a cost-effectiveness analysis.
        Am J Med. 2004; 116: 797-806
        • Bhatt D.L.
        • Topol E.J.
        Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
        Am Heart J. 2004; 148: 263-268
        • Hackam D.G.
        • Goodman S.G.
        • Anand S.S.
        Management of risk in peripheral artery disease: recent therapeutic advances.
        Am Heart J. 2005; 150: 35-40
        • Hankey G.J.
        • Sudlow C.L.
        • Dunbabin D.W.
        Thienopyridine derivatives (ticlopidine, clopidogrel) versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients.
        Cochrane Database Syst Rev. 2000; 2: CD001246
        • Steinhubl S.R.
        • Tan W.A.
        • Foody J.M.
        • Topol E.J.
        Incidence and clinical course of thrombotic thrombocytopenic purpura due to ticlopidine following coronary stenting. EPISTENT Investigators. Evaluation of platelet IIb/IIIa inhibitor for stenting.
        JAMA. 1999; 281: 806-810
        • Majhail N.S.
        • Lichtin A.E.
        Clopidogrel and thrombotic thrombocytopenic purpura: no clear case for casualty.
        Cleve Clin J Med. 2003; 70: 466-470
        • Mangiafico R.A.
        • Fiore C.E.
        Pharmacotherapy for intermittent claudication: from consensus-based to evidence-based treatment.
        Vasc Dis Prev. 2004; 1: 1-15
        • Porter J.M.
        • Cutler B.S.
        • Lee B.Y.
        • et al.
        Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment in chronic occlusive arterial disease patients.
        Am Heart J. 1982; 104: 66-72
        • Ward A.
        • Clissold S.P.
        Pentoxifylline: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy.
        Drugs. 1987; 34: 50-97
        • Lindgarde F.
        • Jelnes R.
        • Bjorkman H.
        • et al.
        Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease.
        Circulation. 1989; 80: 1549-1556
        • Bacher A.
        • Eggensperger E.
        • Koppensteiner R.
        • et al.
        Pentoxifylline attenuates the increase in whole blood viscosity after transfusion.
        Acta Anaesthesiol Scand. 2005; 49: 41-46
        • Baker D.E.
        • Campbell R.K.
        Pentoxifylline: a new agent for intermittent claudication.
        Drug Intell Clin Pharm. 1985; 19: 345-348
        • Chen Y.M.
        • Chiang W.C.
        • Lin S.L.
        • et al.
        Dual regulation of tumor necrosis factor-alpha-induced CCL2/monocyte chemoattractant protein-1 expression in vascular smooth muscle cells by nuclear factor-kappaB and activator protein-1: modulation by type III phosphodiesterase inhibition.
        J Pharmacol Exp Ther. 2004; 309: 978-986
        • Chen Y.M.
        • Tu C.J.
        • Hung K.Y.
        • et al.
        Inhibition by pentoxifylline of TNF-alpha-stimulated fractalkine production in vascular smooth muscle cells: evidence for mediation by NF-kappa B down-regulation.
        Br J Pharmacol. 2003; 138: 950-958
        • Xuereb J.M.
        • Sie P.
        • Boneu B.
        • et al.
        Up-regulation of tissue factor expression by platelet-derived growth factor in human vascular smooth muscle cells in culture—role of mitogen-activated protein kinase and effects of intracellular cyclic AMP.
        Thromb Haemost. 1997; 78: 1520-1526
        • Radack K.
        • Wyderski R.J.
        Conservative management of intermittent claudication.
        Ann Intern Med. 1990; 113: 135-146
        • Hood S.C.
        • Moher D.
        • Barber G.G.
        Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.
        CMAJ. 1996; 155: 1053-1059
        • Ernst E.
        Pentoxyfilline for intermittent claudication: a critical review.
        Angiology. 1994; 45: 339-345
        • Waybill P.N.
        A practical approach to hypertension in the 21st century.
        Vasc Interv Radiol. 2003; 14: 961-975
        • Kambayashi J.
        • Liu Y.
        • Sun B.
        • et al.
        Cilostazol as a unique antithrombotic agent.
        Curr Pharm Des. 2003; 9: 2289-2302
      4., cilostazol NDA #20-863, U.S. patent no. 4,277,479; January 14, 1999.

        • Liu Y.
        • Shakur Y.
        • Yoshitake M.
        • et al.
        Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake.
        Cardiovasc Drug Rev. 2001; 19: 369-386
        • Wang T.
        • Elamb M.B.
        • Forbes W.P.
        • et al.
        Reduction of remnant lipoprotein cholesterol concentrations by cilostazol in patients with intermittent claudication.
        Atherosclerosis. 2003; 171: 337-342
        • Pratt C.M.
        Analysis of the cilostazol safety database.
        Am J Cardiol. 2001; 87: 28D-33D
        • Beebe H.G.
        • Dawson D.L.
        • Cutler B.S.
        • et al.
        A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
        Arch Intern Med. 1999; 159: 2041-2050
        • Conners M.S.
        • Money S.R.
        Can claudication be improved with medication?.
        Semin Vasc Surg. 2002; 15: 237-244
        • Chalothorn D.
        • Zhang H.
        • Clayton J.A.
        • et al.
        Catecholamines augment collateral vessel growth and angiogenesis in hind limb ischemia.
        Am J Physiol Heart Circ Physiol. 2005; 289: H947-H959
        • Dubourg A.
        • Scamuffa R.F.
        An experimental overview of a new vasoactive drug: buflomedil HCl.
        Angiology. 1981; 32: 663-675
        • Pasini F.L.
        • Capecchi P.L.
        • Acciavatti A.
        • et al.
        Pharmacological preconditioning of ischemia.
        Clin Hemorheol Microcirc. 1997; 17: 73-84
        • Pasini F.L.
        • Capecchi P.L.
        • Perri T.D.
        Adenosine and chronic ischemia of the lower limbs.
        Vasc Med. 2000; 5: 243-250
        • Lehert P.
        • Riphagen F.E.
        • Gamand S.
        The effect of naftidrofuryl on intermittent claudication: a meta-analysis.
        J Cardiovasc Pharmacol. 1990; 16: S81-S86
        • Marconi A.
        • Darquenne S.
        • Boulmerka A.
        • et al.
        Naftidrofuryl-driven regulation of endothelial ICAM-1 involves nitric oxide.
        Free Radic Biol Med. 2003; 34: 616-625
        • Barradell L.B.
        • Brogden R.N.
        Oral naftidrofuryl. A review of its pharmacology and therapeutic use in the management of peripheral occlusive arterial disease.
        Drugs Aging. 1996; 8: 299-322
        • Zander J.F.
        • Aerhus L.L.
        • Katusic Z.S.
        • et al.
        Effects of naftidrofuryl on adrenergic nerves, endothelium and smooth muscle in isolated canine blood vessels.
        J Pharmacol Exp Ther. 1986; 239: 760-767
        • Kieffer E.
        • Bahnini A.
        • Mouren X.
        • et al.
        A new study demonstrates the efficacy of naftidrofuryl in the treatment of intermittent claudication: findings of the Naftidrofuryl Clinical Ischemia Study (NCIS).
        Int Angiol. 2001; 20: 58-65
        • D’Hooge D.
        • Lehert P.
        • Clement D.L.
        Naftidrofuryl in quality of life (NIQOL): a Belgian study.
        Int Angiol. 2001; 20: 288-294
        • Hayashi T.
        • Sumi D.
        • Matsui-Hirai H.
        • et al.
        Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism.
        Atherosclerosis. 2003; 168: 23-31
        • Kanayama M.
        • Hashimoto T.
        • Shigenobu K.
        • et al.
        New treatment of lumbar disc herniation involving 5-HT2A receptor inhibitor: a randomized controlled trial.
        J Neurosurg: Spine. 2005; 2: 441-446
        • Rashid M.
        • Manivetb P.
        • Nishiod H.
        • et al.
        Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modelling.
        Life Sci. 2003; 73: 193-207
      5. Martindale: the complete drug reference—Micromedex healthcare series. vol. 117. Micromedex, Greenwood Village, CO2003 ([electronic version])
        • Hiatt W.R.
        Treatment of disability in peripheral arterial disease: new drugs.
        Curr Drug Targets Cardiovasc Haematol Disord. 2004; 4: 227-231
        • Moher D.
        • Pham B.
        • Ausejo M.
        • et al.
        Pharmacological management of intermittent claudication: a meta-analysis of randomised trials.
        Drugs. 2000; 59: 1057-1070
        • Joseph P.
        Alternative therapies—policosanol.
        Am J Health Syst Pharm. 2003; 60: 1112-1115
        • Carbajal D.
        • Arruzazabala M.L.
        • Valdes S.
        • et al.
        Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers.
        Prostaglandins Leukot Essent Fatty Acids. 1998; 58: 61-64
        • Fernandez L.
        • Mas R.
        • Illnait J.
        • et al.
        Policosanol: results of a postmarketing surveillance study of 27,879 patients.
        Curr Ther Res Clin Exp. 1998; 59: 717-722
        • Appleton J.
        Arginine: clinical potential of a semi-essential amino.
        Altern Med Rev. 2002; 7: 512-522
        • Boger R.H.
        • Bode-Boger S.M.
        • Thiele W.
        • et al.
        Restoring vascular nitric oxide formation by l-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
        J Am Coll Cardiol. 1998; 32: 1336-1344
        • Coccheri S.
        • Scondotto G.
        • Agnelli G.
        • et al.
        Arterial Arm of the Suavis (Sulodexide Arterial Venous Italian Study) group. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double blind, multicentre, placebo-controlled study.
        Eur Heart J. 2002; 23: 1057-1065
        • Pittler M.H.
        • Ernst E.
        Ginkgo biloba extract for the treatment of intermittent claudication: a meta-analysis of randomized trials.
        Am J Med. 2000; 108: 276-281
        • Cooper L.T.
        Beraprost for the treatment of intermittent claudication.
        J Am Coll Cardiol. 2003; 41: 1687-1689
      6. Ecraprost: AS 013, Circulase. Drugs R D 2004;5:31–4.

        • Dey S.
        • Mukherjee D.
        Clinical perspectives on the role of anti-platelet and statin therapy in patients with vascular diseases.
        Curr Vasc Pharmacol. 2003; 1: 329-333
        • Aronow W.S.
        • Nayak D.
        • Woodworth S.
        • et al.
        Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment.
        Am J Cardiol. 2003; 92: 711-712
        • Daskalopoulou S.S.
        • Daskalopoulos M.E.
        • Liapis C.D.
        • et al.
        Peripheral arterial disease: a missed opportunity to administer statins so as to reduce cardiac morbidity and mortality.
        Curr Med Chem. 2005; 12: 443-452
        • Rosenson R.S.
        Statins in atherosclerosis lipid-lowering agents with antioxidant capabilities.
        Atherosclerosis. 2004; 173: 1-12
        • Davignon J.
        • Jacob R.F.
        • Mason R.P.
        The antioxidant effects of statins.
        Coron Artery Dis. 2004; 15: 251-258
        • Kang S.
        • Wu Y.
        • Li X.
        Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis.
        Atherosclerosis. 2004; 177: 433-442
        • Grobbee D.E.
        • Bots M.L.
        Atherosclerotic disease regression with statins: studies using vascular markers.
        Int J Cardiol. 2004; 96: 447-459
        • Artenie A.
        • Artenie R.
        • Ungureanu D.
        • et al.
        HDL-cholesterol—active or passive participant in atherosclerosis pathogenesis?.
        Rev Med Chir Soc Med Nat Iasi. 2004; 108: 503-508
        • MacRury S.M.
        • Muir M.
        • Hume R.
        Seasonal and climatic variation in cholesterol and Vitamin C: effect of Vitamin C supplementation.
        Scott Med J. 1992; 37: 49-52
        • Leng G.C.
        • Horrobin D.F.
        • Fowkes F.G.
        • et al.
        Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study.
        Arterioscler Thromb. 1994; 14: 471-478
        • Lonn E.
        • Yusuf S.
        • Dzavik V.
        • et al.
        Effects of ramipril and Vitamin E on arteriosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE).
        Circulation. 2001; 103: 919-925
        • Yusuf S.
        • Sleight P.
        • Pogue J.
        • et al.
        The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.
        N Engl J Med. 2000; 342: 145-153
        • Hobbs S.D.
        • Thomas M.E.
        • Bradbury A.W.
        Manipulation of the rennin angiotensin system in peripheral arterial disease.
        Eur J Endovasc Surg. 2004; 28: 573-582
        • Muzaffar S.
        • Shukla N.
        • Lobo C.
        • et al.
        Iloprost inhibits NADPH oxidase expression and superoxide release in porcine pulmonary arteries and cells stimulated with thromboxane A2, isoprostane F2α and cytokines.
        Br J Pharmacol. 2004; 141: 488-496
        • Van Beek T.A.
        • Bombardelli E.
        • Morazzoni P.
        • Peterlongo F.
        Ginkgo biloba L.
        Fitoterapia. 1998; 69: 195-244
        • Kleijnen J.
        • Knipschild P.
        • Ter Riet G.
        Vitamin E and cardiovascular disease.
        Eur J Clin Pharmacol. 1989; 37: 541-544
      7., website visited on 27 April 2005.

        • Kleijnen J.
        • Knipschild P.
        Ginkgo biloba.
        Lancet. 1992; 340: 1136-1139
        • MacRury S.M.
        • Muir M.
        • Hume R.
        Seasonal and climatic variation in cholesterol and Vitamin C: effect of Vitamin C supplementation.
        Scott Med J. 1992; 37: 49-52
        • Leng G.C.
        • Horrobin D.F.
        • Fowkes F.G.
        • et al.
        Plasma essential fatty acids, cigarette smoking, and dietary antioxidants in peripheral arterial disease. A population-based case-control study.
        Arterioscler Thromb. 1994; 14: 471-478
        • Tornwall M.E.
        • Virtamo J.
        • Haukka J.K.
        • et al.
        Prospective study of diet, lifestyle, and intermittent claudication in male smokers.
        Am J Epidemiol. 2000; 151: 892-901
        • Silvestro A.
        • Scopacasa F.
        • Oliva G.
        • et al.
        Vitamin C prevents endothelial dysfunction induced by acute exercise in patients with intermittent claudication.
        Atherosclerosis. 2002; 165: 277-283
        • Kleijnen J.
        • Mackerras D.
        Vitamin E for intermittent claudication.
        Cochrane Database Syst Rev. 2000; : CD000987
        • Kleijnen J.
        • Knipschild P.
        • Ter Riet G.
        Vitamin E and cardiovascular disease.
        Eur J Clin Pharmacol. 1989; 37: 541-544
        • Barandon L.
        • Leroux L.
        • Dufourcq P.
        • et al.
        Gene therapy for chronic peripheral arterial disease: what role for the vascular surgeon?.
        Ann Vasc Surg. 2004; 18: 758-765
        • Blann A.D.
        • Belgore F.M.
        • McCollum C.N.
        • et al.
        Vascular endothelial growth factor and its receptor, Flt-1, in the plasma of patients with coronary or peripheral atherosclerosis, or type II diabetes.
        Clin Sci (Lond). 2002; 102: 187-194
        • Donnelly R.
        • Yeung J.M.C.
        Therapeutic angiogenesis: a step forward in intermittent claudication.
        Lancet. 2002; 359: 2048-2050
        • Rajagopalan S.
        • Mohler E.R.
        • Lederman R.J.
        • et al.
        Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.
        Circulation. 2003; 108: 1933-1938
        • Rajagopalan S.
        • Olin J.W.
        • Young S.
        • et al.
        Design of the Del-1 for therapeutic angiogenesis trial (DELTA-1), a phase II multicentre, double-blind, placebo-controlled trial of VLTS-589 in subjects with intermittent claudication secondary to peripheral arterial disease.
        Hum Gene Ther. 2004; 15: 619-624
        • Heistad D.D.
        • Armstrong M.L.
        • Lopez J.A.
        What causes spasm of atherosclerotic arteries? Is regression of plaques beneficial?.
        Trans Am Clin Climatol Assoc. 1989; 101: 103-110
        • Hegle R.A.
        Is regression of coronary atherosclerosis possible by infusion recombinant apolipoprotein A-I?.
        JAMC. 2004; 170: 954
        • Taylor A.
        • Shaw L.J.
        • Fayad Z.
        • et al.
        Tracking atherosclerosis regression: a clinical tool in preventive cardiology.
        Atherosclerosis. 2005; 180: 1-10
        • De Backer T.L.
        • Vander Stichele R.H.
        • Warie H.H.
        • et al.
        Oral vasoactive medication in intermittent claudication: utile or futile.
        Eur J Clin Pharmacol. 2000; 56: 199-206
        • Diehm C.
        • Kareem S.
        • Lawall H.
        Epidemiology of peripheral arterial disease.
        Vasa. 2004; 33: 183-189
        • Chan A.W.
        Expanding roles of the cardiovascular specialists in panvascular disease prevention and treatment.
        Can J Cardiol. 2004; 20: 535-544